CAS 2375840-87-0

Formula: C20H14ClF2NO5S

InChI: InChI=1S/C20H14ClF2NO5S/c1-29-20(26)12-7-14(21)19(25)18(8-12)30(27,28)24-17-9-13(15(22)10-16(17)23)11-5-3-2-4-6-11/h2-10,24-25H,1H3

InChI key: YSTSHUWHIDBZAK-UHFFFAOYSA-N

SMILES: COC(=O)C1=CC(=C(C(=C1)Cl)O)S(=O)(=O)NC2=C(C=C(C(=C2)C3=CC=CC=C3)F)F

NDI-091143

CAS: 2375840-87-0

NDI-091143

Formula: C₂₀H₁₄ClF₂NO₅S

Purity: ≥95%

Molecular weight: 453.84

Ref: 54-BUP05746

Methyl 3-Chloro-5-(N-(4,6-Difluoro-[1,1'-Biphenyl]-3-Yl)Sulfamoyl)-4-Hydroxybenzoate

CAS: 2375840-87-0

Methyl 3-Chloro-5-(N-(4,6-Difluoro-[1,1'-Biphenyl]-3-Yl)Sulfamoyl)-4-Hydroxybenzoate

Formula: C₂₀H₁₄ClF₂NO₅S

Purity: 98%

Molecular weight: 453.84

Ref: 54-PC108476

NDI-091143

CAS: 2375840-87-0

NDI-091143 is a potent and high-affinity human ATP-citrate lyase (ACLY) inhibitor with an IC50 of 2.1 nM (ADP-Glo assay),indirectly disrupting citrate binding

Formula: C₂₀H₁₄ClF₂NO₅S

Purity: 97.03% - ≥95%

Color and Shape: Solid

Molecular weight: 453.844

Ref: TM-T7424

NDI-091143

CAS: 2375840-87-0

Methyl 3-chloro-5-(N-(4,6-difluoro-[1,1'-biphenyl]-3-yl)sulfamoyl)-4-hydroxybenzoate

Formula: C₂₀H₁₄ClF₂NO₅S

Purity: 98%

Molecular weight: 453.84

Ref: IN-DG01149781

Methyl 3-chloro-5-(N-(4,6-difluoro-[1,1′-biphenyl]-3-yl)sulfamoyl)-4-hydroxybenzoate

CAS: 2375840-87-0

Formula: C₂₀H₁₄ClF₂NO₅S

Purity: 98%

Molecular weight: 453.84

Ref: 10-F546825

6-Chloro-4-fluoropyridine-3-boronic acid

CAS: 2375840-87-0

Formula: C₂₀H₁₄ClF₂NO₅S

Purity: 98%

Color and Shape: Solid

Molecular weight: 453.8437

Ref: IN-DA01JTEG

NDI-091143

CAS: 2375840-87-0

NDI-091143 is a drug that inhibits prenylation, which is the process whereby proteins are modified by the attachment of a chain of seven carbon atoms called an isoprenoid. This process is important for cancer cell survival and the maintenance of healthy cells. Inhibiting this process leads to apoptosis, or cell death, in cancer cells. NDI-091143 has been shown to have potent inhibition against acetylated proteins in vitro. The drug has also been shown to be hydrophobic and druggable, meaning it can cross the blood brain barrier and enter cells. Additionally, NDI-091143 has been found to bind to cavity surfaces in cryo-electron microscopy studies. The drug inhibits cancer cell growth by binding to a specific site on HMG CoA reductase which results in reduced levels of cholesterol synthesis.
NDI-091143's mechanism of action involves inhibiting the enzyme 3β-hydroxyster

Formula: C₂₀H₁₄ClF₂NO₅S

Purity: Min. 95%

Molecular weight: 453.84 g/mol

Ref: 3D-AVD84087